Lineage Cell Therapeutics
LCTX
96 hedge funds and large institutions have $161M invested in Lineage Cell Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
10% more capital invested
Capital invested by funds: $146M → $161M (+$15.1M)
4% more funds holding
Funds holding: 92 → 96 (+4)
3.43% more ownership
Funds ownership: 44.75% → 48.18% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
97% less call options, than puts
Call options by funds: $3K | Put options by funds: $103K
Top Buyers
| 1 |
BlackRock
New York
|
+$15.9M |
| 2 |
BC
Broadwood Capital
New York
|
+$7.21M |
| 3 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
+$6.01M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.34M |
Top Sellers
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$357K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$268K |
| 3 |
Two Sigma Investments
New York
|
-$239K |
| 4 |
Citigroup
New York
|
-$222K |
| 5 |
Morgan Stanley
New York
|
-$198K |
LCTX Hedge Fund Activity: Q1 2017 in Review
96 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2017, worth a combined $161M — up 10% from $146M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LCTX positions and 5 closed out — a net gain of 9 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $15.9M. The largest seller was Manatuck Hill Partners, cutting an estimated $357K.
- 96 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2017, up from 92 in Q4 2016.
- Funds reported $161M of Lineage Cell Therapeutics stock for Q1 2017, up 10% quarter-over-quarter.
- 14 funds opened new Lineage Cell Therapeutics positions in Q1 2017 and 5 closed out, a net change of +9 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2017 was BlackRock, an estimated $15.9M added.
- The largest Lineage Cell Therapeutics seller in Q1 2017 was Manatuck Hill Partners, an estimated $357K sold.
Based on aggregated 13F filings for Q1 2017.